NDLI: The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD

Please wait, while we are loading the content...

The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD

Content Provider	Semantic Scholar
Author	Yawn, Barbara P. Raphiou, Ibrahim H. Hurley, Judith S. Dalal, Anand A.
Copyright Year	2010
Abstract	Exacerbations contribute significantly to the morbidity of COPD, leading to an accelerated decline in lung function, reduced functional status, reduced health status and quality of life, poorer prognosis and increased mortality. Prevention of exacerbations is thus an important goal of COPD management. In patients with COPD, treatment with a combination of the inhaled corticosteroid fluticasone propionate (250 microg) and the long-acting beta(2)-agonist salmeterol (50 microg) in a single inhaler (250/50 microg) is an effective therapy option that has been shown to reduce the frequency of exacerbations, to improve lung function, dyspnea and health status, and to be relatively cost-effective as a COPD maintenance therapy. Importantly, results of various studies suggest that fluticasone propionate and salmeterol have synergistic effects when administered together that improve their efficacy in controlling symptoms and reducing exacerbations. The present non-systematic review summarizes the role of fluticasone propionate/salmeterol combination therapy in the prevention of exacerbations of COPD and its related effects on lung function, survival, health status, and healthcare costs.
Starting Page	165
Ending Page	178
Page Count	14
File Format	PDF HTM / HTML
PubMed reference number	20631816v1
Volume Number	5
Journal	International journal of chronic obstructive pulmonary disease
Alternate Webpage(s)	http://ftp.ncbi.nlm.nih.gov/pub/pmc/4b/cb/copd-5-165.PMC2898089.pdf
Alternate Webpage(s)	https://www.dovepress.com/getfile.php?fileID=6439
Language	English
Access Restriction	Open
Subject Keyword	Adrenal Cortex Hormones Chronic Obstructive Airway Disease Dyspnea Fluticasone propionate Forecast of outcome Inhaler Morbidity - disease rate Patients Propionates Respiratory physiology fluticasone / salmeterol
Content Type	Text
Resource Type	Article

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in